



Guideline

Guidelines for Pediatric Unrelated Cord Blood Transplantation—Unique Considerations



Ann Dahlberg^{1,*}, Joanne Kurtzberg^{2,3}, Jaap Boelens⁴, Caridad Martinez^{5,6}, Paul Carpenter¹, Priti Tewari⁷ American Society for Transplantation and Cellular Therapy Cord Blood Special Interest Group

¹ Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, Washington

² Marcus Center for Cellular Cures, Duke University, Durham, North Carolina

³ Department of Pediatrics, Duke University, Durham, North Carolina

⁴ Stem Cell Transplantation and Cellular Therapies, Memorial Sloan Kettering Cancer Center, New York, New York

⁵ Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Houston, Texas

⁶ Texas Children's Hospital, Houston, Texas

⁷ Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas

Article history:

Received 8 September 2021

Accepted 19 September 2021

Key Words:

Pediatric cord blood transplantation
Guidelines

A B S T R A C T

Cord blood (CB) is the stem cell source of choice for approximately 30% of pediatric patients undergoing hematopoietic cell transplantation. Cord blood is readily available and is a particularly appealing stem cell source for patients who lack appropriate HLA-matched related or unrelated donors. Pediatric cord blood transplant (CBT) recipients have low rates of disease relapse in the malignant setting and very low rates of chronic graft-versus-host disease (GVHD). In addition, CB has unique properties that make it the stem cell source of choice for some nonmalignant conditions such as metabolic disorders. This review provides evidence-based and experience-based pediatric-specific guidelines for CBT including considerations for infectious disease management, CB unit selection and infusion, conditioning regimen selection, and GVHD management. In addition, it covers unique bedside considerations for pediatric patients and CB banking. In concert with the other topic specific CB guidelines previously published in this series, it provides a comprehensive overview of the clinical management of pediatric CBT.

© 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Although registry data indicate an overall decline in the use of umbilical cord blood in recent years, it continues to be the stem cell source for approximately 30% of children undergoing hematopoietic cell transplantation (HCT). This is likely explained by advantages that are more often attainable in children because of generally favorable CB cell doses and unique disease indications for HCT (FAQ1). Perhaps most pertinent is the observation that overall chronic graft-versus-host disease (cGVHD) and relapse-free survival in children after CBT is high, with the greater propensity for infectious complications being mitigated by optimal clinical practices (FAQ2). The following guideline focuses on unique questions related to allogeneic umbilical cord transplantation for pediatrics.

FAQ1: WHAT ARE THE ADVANTAGES OF CBT?

- CB units (CBU) are readily available and provide a viable treatment alternative for patients without an HLA-matched sibling or unrelated donor (URD), a situation that disproportionately impacts ethnic and racial minorities [1] (Table 1).
- Additionally, CBT recipients have equivalent overall survival (OS) with evidence of decreased relapse rates particularly in comparison to HLA matched related donor transplants. This makes CBT particularly appealing in high-risk leukemia where relapse is of primary concern [2,3]. In fact, the presence of minimal residual disease (MRD) at the time of transplantation does not impact disease-free survival in recipients of CBT [4] unlike other stem cell sources where there is a significant risk of relapse (hazard ratio [HR] 3.65 [2.53-5.27]) and decreased overall survival (HR 2.36 [1.73-3.22]) when MRD is present [5].

Financial disclosure: See Acknowledgments on page 971.

*Correspondence and reprint requests: Ann Dahlberg, MD, MD-B306; 1100 Fairview Avenue N, Seattle, WA 98109.

E-mail address: adahlber@fredhutch.org (A. Dahlberg).

<https://doi.org/10.1016/j.tct.2021.09.013>

2666-6367/© 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Table 1
Advantages of CBT

Potential benefit	Malignant Disease	Nonmalignant Disease [11]
Ready availability	Yes	Yes
Less stringent HLA-matching potentially relevant to ethnic/racial minorities with fewer MRD/MUD options	Yes	Yes
Favorable cell doses are more readily achievable in pediatric CBT recipients	Yes	Yes
Equivalent survival and low risk or relapse, even when MRD present at time of CBT	Yes	Not applicable
Low rates or lower severity of chronic GVHD compared to URDs	Yes	Yes
Improved cGVHD-leukemia free survival (cGVHD-LFS) (measure of quality of life)	Yes	Not applicable
Donor stem cell source of choice for inborn errors of metabolism	Not applicable	Yes

- Recipients of CBT have low rates of chronic GVHD similar to those receiving HLA-matched sibling donor transplants and significantly lower than HLA-matched unrelated donor (MUD) recipients [6].
- Improved quality of life (such as timing of return to school) and reduced risk for mortality is also evident in the composite endpoint of cGVHD-LFS which was significantly improved in CBT recipients as compared to recipients of unrelated donor transplants [7].
- Durable donor chimerism is well established in both malignant and, especially, non-malignant diseases.
- We believe CBT should be considered in patients with very high-risk leukemias and MRD positivity at the time of transplant where graft-versus-leukemia is of particular importance. Emerging data indicate that the immunobiology of CBT may be distinct from other stem cell sources and contribute to the lower rates of relapse. For example, HLA-loss as a major mechanism of post-transplantation relapse has not been observed in CBT [8].

FAQ 2. ARE THERE PEDIATRIC-SPECIFIC PRE-CBT INFECTIOUS DISEASE EVALUATIONS TO CONSIDER?

Cord blood-specific infectious disease evaluations are covered in “Guidelines for Infection Prophylaxis, Monitoring and Therapy in Cord Blood Transplantation” [9] from this series. Specific to pediatrics is the importance of comprehensive infectious disease workup, intensive viral monitoring, use of prophylaxis, and early initiation of treatment. Regular post-transplantation surveillance for adenovirus and HHV-6 are should also be strongly considered.

Many centers have cytomegalovirus (CMV) monitoring guidelines specific to cord blood recipients. Letermovir is a promising medication for the prevention of CMV reactivation and disease. This medication is not yet approved in the pediatric population, and so intensive monitoring ± high-dose acyclovir/valacyclovir or ganciclovir is used to prevent CMV disease.

FAQ 3. ARE THERE UNIQUE CONSIDERATIONS FOR CELL DOSE OR CELL INFUSION IN PEDIATRIC CBT RECIPIENTS?

Please refer to “Guidelines for Cord Blood Unit Thaw and Infusion” in this series for details on considerations for cord

blood infusion [10]. Please also refer to “Guidelines for Cord Blood Unit Selection” in this series for in-depth discussion of CBU selection [11].

The most important factors related to CBT outcomes are HLA match and total nucleated cell (TNC) dose. For pediatric CBT recipients with malignant indications for HCT, successful engraftment along with other outcomes improve with higher CB cell dose [12–17]. The absolute minimum cell dose for an unmanipulated single CB should be at least 2.5×10^7 TNC/kg, with target cell dose 4×10^7 TNC/kg. For nonmalignant indications, a targeted cell dose greater than 4×10^7 /kg is recommended, with higher doses recommended for patients with lesser HLA-matched cord (4/6) or severe aplastic anemia [18]. For pediatrics single cord is preferred over double cord when adequate cell dose is available [19]. These cell doses are based on the pre-cryopreservation cell dose data. CD34 cell dose can be another important consideration that can affect engraftment and outcomes.

The minimum acceptable CD34 cell dose is at least 1.5×10^5 CD34/kg [20,21]. During CBU selection, higher-level HLA match takes precedence over cell dose [17,22], assuming minimum cell dose criteria have been met.

FAQ 4. WHAT ARE THE MOST COMMON CONDITIONING REGIMENS USED IN PEDIATRIC CBT RECIPIENTS?

A comprehensive review of cord blood regimens is provided in “Guidelines for Adult Patient Selection and Conditioning Regimens in Cord Blood Transplant Recipients With Hematologic Malignancies and Aplastic Anemia” [23]. The most common conditioning approaches in pediatric patients are shown below. For nonmalignant diseases in particular, conditioning regimens may be altered based on disease and patient clinical status (Table 2).

FAQ5: ARE THERE SPECIFIC GVHD MANAGEMENT CONSIDERATIONS IN CHILDREN?

In general, GVHD management in children does not differ from adults receiving CBT (reviewed in detail in “Guidelines for the Prevention and Management of Graft-Versus-Host Disease After Cord Blood Transplantation” [25]). Most common GVHD prophylaxis regimens use a calcineurin inhibitor (CNI) and mycophenolate mofetil (MMF) in the first 2 to 6 months

Table 2
Conditioning Regimens Based on Disease and Patient Clinical Status

Conditioning Regimens	Malignant Disease	Nonmalignant Disease
Myeloablative	FLU (75 mg/m ²), CY (120 mg/kg), 12–13.2 Gy TBI	BU targeted (90 mg × h/L), CY (200 mg/kg), ATG*, ± FLU
	BU targeted, CY (200 mg/kg)	
Reduced Intensity	FLU (150 mg/m ²), CY (50 mg/kg), TT (10 mg/kg), 4 Gy TBI [24]	BU targeted (60 mg × h/L), FLU, ATG*

FLU indicates fludarabine; CY, cyclophosphamide; TBI, Total Body Irradiation; BU, busulfan; TT, thiotepa.

* Consider withholding ATG in the setting of significant viral infections.

after transplantation. In vivo T-cell depletion with ATG is an alternative immune suppressive strategy; however, its use is controversial if the underlying disease indication is malignancy and generally avoided because of higher risk of viral reactivation, delayed immune reconstitution, and concern for increased NRM and relapse. If ATG is given, ATG pharmacokinetics should be considered to reduce post-transplantation ATG exposure and enhance immune reconstitution [26]. The majority of children will develop acute GVHD; however, severe (grade III to IV) GVHD occurs in a minority of patients (13%) [19]. Of note MMF taper should be considered once systemic corticosteroids are added for the primary treatment of acute GVHD as no study has yet demonstrated that CNI+MMF+corticosteroid is superior to CNI+corticosteroids for acute GVHD management. Acute GVHD more commonly affects skin and gut rather than liver and typically is very responsive to corticosteroids. The intensity of corticosteroid therapy should attempt to balance the risk for viral reactivation without compromising GVHD control. For patients requiring second- and third-line therapy for GVHD, relatively less immunosuppressive approaches such as extracorporeal photopheresis or mesenchymal stem cells if available could be considered, particularly in patients in whom viral infection is complicating or driving GVHD.

FAQ6. WHAT IS PRE-ENGRAFTMENT SYNDROME AND HOW TO BEST MANAGE IT?

A unique complication following CBT is pre-engraftment syndrome (PES) [27–29]. This can occur commonly and manifest with noninfectious fevers, rash, fluid retention, and less commonly tachypnea and hypoxia in the peri-engraftment period [30]. These symptoms are otherwise unexplained and not responsive to antimicrobial changes. Pediatric CBT recipients should be monitored for PES. When there is evidence of PES, infectious causes should first be ruled out with blood cultures, urine cultures, viral polymerase chain reactions (PCRs), stool cultures/PCRs, nasal wash or radiology evaluations when clinically appropriate. If an alternate etiology is not identified, short-course steroids should be initiated without delay to treat and manage PES. As described in previously published guidelines in this series, the recommended steroid and dose is methylprednisolone at 1 to 2 mg/kg/day for 3 days and then weaned off rapidly within a week of engraftment [25]. Although 1 mg/kg is the standard adult PES dose, the Bone and Marrow Transplant Clinical Trials Network (BMT CTN) study 0501 used 2 mg/kg in a pediatric population, and so this should be considered, particularly in the setting of significant PES symptoms [19]. If symptoms persist beyond 6 days, the patient should be considered to have hyperacute/acute GVHD and treated with a steroid course as deemed appropriate by treating clinician.

FAQ 7. ARE THERE UNIQUE BEDSIDE CONSIDERATIONS IN PEDIATRIC PATIENTS RECEIVING CBT AS COMPARED TO OTHER DONOR SOURCES?

In general, the management of patients before and after CBT is similar to recipients of other stem cell sources; however, there are a few unique considerations of which to be aware for those administering care at the bedside. CBU thaw and infusion guidelines have been recently published and can be referenced for standard operating procedures for CB processing and infusion [10].

- Of particular note, for children, is the decision between “dilute” and “dilute and wash” for product preparation. The

latter should be considered in patients less than 20 kg to control infusion volume and avoid fluid overload.

- Fluid balance and vital signs should be monitored closely at the bedside because fluid overload can exacerbate common infusion reactions such as hypertension, as well as rare but serious reactions such as Takotsubo cardiomyopathy [31].
- Hypertension should be managed with antihypertensive medications (hydralazine), as well as adjusting infusion rate and providing diuresis if indicated.
- The timing from thaw or thaw/wash to infusion should be less than 2 hours if feasible to optimize the viability and potency of the cord blood cells.
- For double cord blood transplants, units should be thawed and infused serially, allowing sufficient time between unit infusions to assess for adverse reactions.
- Non red cell depleted cryopreserved CBUs contain sufficient RBCs to cause hemolytic transfusion reactions in small children. The volume of residual (post processing) RBCs in any CBU should be known before thaw. If ABO incompatibility exists, then thaw and wash or a post thaw RBC depletion should be strongly considered or, if possible, an alternative CBU should be selected.

FAQ 8. WHAT ARE THE LONG-TERM SIDE EFFECTS OF PEDIATRIC CBT AND ARE THEY DIFFERENT FROM OTHER DONOR SOURCES?

Pediatric CBT recipients generally have a similar long-term side effect profile as those patients receiving comparable conditioning regimens but alternate donor sources. There are, however, a few notable differences.

- Recipients of CBT are at significantly lower risk of chronic GVHD as compared to those receiving other MUD/MMUD stem cell sources. Studies have consistently shown the incidence of chronic GVHD by NIH Consensus grading to be around 20% to 25% in both children and adults, with the majority of cases being mild or moderate [32–35].
- Interestingly, multiple large centers have noted that recipients of CBTs appear to develop atopic dermatitis that is distinct from chronic GVHD and typically responds to topical agents and does not require continuation or escalation of systemic immune suppression [36].
- Late acute-gut GVHD is a manifestation of CBT that is relatively more common than classic chronic GVHD manifestations [37].
- Historically, recipients of CBTs were considered to have delayed T-cell immune reconstitution (IR) as compared to other donor sources, placing them at increased risk for early post-transplantation infectious complications [38–40]. More recent literature suggests this may not be the case in the absence of ATG. Furthermore, early T-cell IR (CD4+) in CBT patients is associated with improved survival. Decreasing ATG exposure or eliminating ATG from conditioning regimens for patients with malignant indications for transplantation has the advantage of improving IR and survival outcomes and is the standard approach for most large CBT centers in the United States [26]. Delayed IR in CBT recipients does not impact recommendations for revaccination in these patients, and established guidelines should be followed for initiation of revaccination [41].

FAQ 9. DO YOU RECOMMEND PUBLIC OR PRIVATE BANKING OF CB FROM SIBLINGS?

Cord donation for public banking continues to be recommended to help increase the representation in our national

and international CB banks, especially for populations that continue to be underrepresented in the National Marrow Donor Program (NMDP) [42–44]. In addition, focus on banking of large, high-quality CBUs will further improve the inventory of CBUs available for transplantation.

The one exception to this is consideration of direct donation (privately or to a commercial/public bank that may bank units free of charge) for families that have another child who may require future allogeneic stem cell transplantation where an HLA-matched sibling graft is the preferred stem cell source. This would most commonly occur in nonmalignant conditions such as sickle cell disease, thalassemia, Wiscott-Aldrich syndrome, Hurler's syndrome, adrenoleukodystrophy, and other inborn errors of metabolism [45]. The carrier state of the CBU donor should be determined before use of a sibling CBU. In certain conditions, use of a carrier donor is contraindicated. Families electing to bank CBUs in private banks should confirm that appropriate quality assurance and regulatory review has occurred and that unit processing results in sufficient cell dose for future use. Contact NMDP for further guidance regarding choice of specific private banks or public banks that may waive fees for families who have a child with a potential indication for allogeneic transplantation [46].

ACKNOWLEDGMENTS

Financial disclosure: None.

Conflict of interest statement: There are no conflicts of interest to report.

Authorship statement: A.D., P.T., P.C. wrote the manuscript. All authors reviewed, edited and approved the manuscript.

REFERENCES

- Barker JN, Boughan K, Dahi PB, et al. Racial disparities in access to HLA-matched unrelated donor transplants: a prospective 1312-patient analysis. *Blood Adv.* 2019;3:939–944.
- Brunstein CG, Gutman JA, Weisdorf DJ, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. *Blood.* 2010;116:4693–4699.
- Milano F, Gooley T, Wood B, et al. Cord-Blood Transplantation in Patients with Minimal Residual Disease. *N Engl J Med.* 2016;375:944–953.
- Politikos I, Lavery JA, Hilden P, et al. Robust CD4+ T-cell recovery in adults transplanted with cord blood and no antithymocyte globulin. *Blood Adv.* 2020;4:191–202.
- Buckley SA, Wood BL, Othus M, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. *Haematologica.* 2017;102:865–873.
- Arora M, Cutler CS, Jagasia MH, et al. Late acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. *Biol Blood Marrow Transplant.* 2016;22:449–455.
- Keating AK, Langenhorst J, Wagner JE, et al. The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia. *Blood Adv.* 2019;3:1118–1128.
- Vago L, Toffalori C, Ahci M, et al. Incidence of HLA loss in a global multicentric cohort of post-transplantation relapses: results from the Hlaloss Collaborative Study. *Blood.* 2018:132.
- Olson AL, Politikos I, Brunstein C, et al. Guidelines for infection prophylaxis, monitoring and therapy in cord blood transplantation. *Transplant Cell Ther.* 2021;27:359–362.
- Scaradavou A, Avecilla ST, Tonon J, et al. Guidelines for cord blood unit thaw and infusion. *Biol Blood Marrow Transplant.* 2020;26:1780–1783.
- Politikos I, Davis E, Nhaiisi M, et al. Guidelines for Cord Blood Unit Selection. *Biol Blood Marrow Transplant.* 2020;26:2190–2196.
- Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. *Lancet.* 2007;369(9577):1947–1954.
- Herr AL, Kabbara N, Bonfim CM, et al. Long-term follow-up and factors influencing outcomes after related HLA-identical cord blood transplantation for patients with malignancies: an analysis on behalf of Eurocord-EBMT. *Blood.* 2010;116:1849–1856.
- Kurtzberg J, Laughlin M, Graham ML, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. *N Engl J Med.* 1996;335:157–166.
- Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. *N Engl J Med.* 1997;337:373–381.
- Kurtzberg J, Prasad VK, Carter SL, et al. Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. *Blood.* 2008;112:4318–4327.
- Barker JN, Scaradavou A, Stevens CE. Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. *Blood.* 2010;115:1843–1849.
- Prasad VK, Kurtzberg J. Umbilical cord blood transplantation for non-malignant diseases. *Bone Marrow Transplant.* 2009;44:643–651.
- Wagner Jr. JE, Eapen M, Carter S, et al. One-unit versus two-unit cord-blood transplantation for hematologic cancers. *N Engl J Med.* 2014;371:1685–1694.
- Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and non-malignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. *Blood.* 2002;100:1611–1618.
- Barker JN, Kurtzberg J, Ballen K, et al. Optimal practices in unrelated donor cord blood transplantation for hematologic malignancies. *Biol Blood Marrow Transplant.* 2017;23(6):882–896.
- Eapen M, Klein JP, Ruggeri A, et al. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. *Blood.* 2014;123:133–140.
- Metheny L, Politikos I, Ballen KK, et al. Guidelines for adult patient selection and conditioning regimens in cord blood transplant recipients with hematologic malignancies and aplastic anemia. *Transplant Cell Ther.* 2021;27(4):286–291.
- Ponce DM, Sauter C, Devlin S, et al. A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation. *Biol Blood Marrow Transplant.* 2013;19:799–803.
- Ponce DM, Politikos I, Alousi A, et al. Guidelines for the prevention and management of graft-versus-host disease after cord blood transplantation. *Transplant Cell Ther.* 2021;27(7):540–544.
- Admiraal R, Lindemans CA, van Kesteren C, et al. Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation. *Blood.* 2016;128(23):2734–2741.
- Park M, Lee SH, Lee YH, et al. Pre-engraftment syndrome after unrelated cord blood transplantation: a predictor of engraftment and acute graft-versus-host disease. *Biol Blood Marrow Transplant.* 2013;19(4):640–646.
- Patel KJ, Rice RD, Hawke R, et al. Pre-engraftment syndrome after double-unit cord blood transplantation: a distinct syndrome not associated with acute graft-versus-host disease. *Biol Blood Marrow Transplant.* 2010;16(3):435–440.
- Kanda J, Kaynar L, Kanda Y, et al. Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment. *Bone Marrow Transplant.* 2013;48(7):926–931.
- Brownback KR, Simpson SQ, McGuirk JP, et al. Pulmonary manifestations of the pre-engraftment syndrome after umbilical cord blood transplantation. *Ann Hematol.* 2014;93(5):847–854.
- Ballen K, Logan BR, Chitphakdithai P, et al. Unlicensed umbilical cord blood units provide a safe and effective graft source for a diverse population: a study of 2456 umbilical cord blood recipients. *Biol Blood Marrow Transplant.* 2020;26:745–757.
- Alsultan A, Giller RH, Gao D, et al. GVHD after unrelated cord blood transplant in children: characteristics, severity, risk factors and influence on outcome. *Bone Marrow Transplant.* 2011;46:668–675.
- Fatobene G, Storer BE, Salit RB, et al. Disability related to chronic graft-versus-host disease after alternative donor hematopoietic cell transplantation. *Haematologica.* 2019;104:835–843.
- Gutman JA, Ross K, Smith C, et al. Chronic graft versus host disease burden and late transplant complications are lower following adult double cord blood versus matched unrelated donor peripheral blood transplantation. *Bone Marrow Transplant.* 2016;51:1588–1593.
- Ponce DM, Gonzales A, Lubin M, et al. Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match. *Biol Blood Marrow Transplant.* 2013;19:904–911.
- Wei J, Zhang Y, Xu H, Jin J, Zhang J. Atopic dermatitis-like presentation of graft-versus-host disease: a novel form of chronic cutaneous graft-versus-host disease. *J Am Acad Dermatol.* 2013;69:34–39.
- Newell LF, Flowers ME, Gooley TA, et al. Characteristics of chronic GVHD after cord blood transplantation. *Bone Marrow Transplant.* 2013;48:1285–1290.
- Kanda J, Chiu LW, Szabolcs P, et al. Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and

- matched unrelated donor hematopoietic cell transplantation. *Biol Blood Marrow Transplant.* 2012;18:1664–1676. e1661.
39. Sauter C, Abboud M, Jia X, et al. Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin. *Biol Blood Marrow Transplant.* 2011;17:1460–1471.
 40. Bejanyan N, Brunstein CG, Cao Q, et al. Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. *Blood Adv.* 2018;2(8):909–922.
 41. Carpenter PA, Englund JA. How I vaccinate blood and marrow transplant recipients. *Blood.* 2016;127:2824–2832.
 42. Shearer WT, Lubin BH, Cairo MS, et al. Cord blood banking for potential future transplantation. *Pediatrics.* 2017;140(5) e20172695.
 43. Mayani H, Wagner JE, Broxmeyer HE. Cord blood research, banking, and transplantation: achievements, challenges, and perspectives. *Bone Marrow Transplant.* 2020;55:48–61.
 44. Thornley I, Eapen M, Sung L, Lee SJ, Davies SM, Joffe S. Private cord blood banking: experiences and views of pediatric hematopoietic cell transplantation physicians. *Pediatrics.* 2009;123:1011–1017.
 45. Gluckman E, Ruggeri A, Rocha V, et al. Family-directed umbilical cord blood banking. *Haematologica.* 2011;96:1700–1707.
 46. Prasad VK, Lucas KG, Kleiner GI, et al. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. *Biol Blood Marrow Transplant.* 2011;17:534–541.